Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...
Pfizer delayed the announcement of its COVID-19 vaccine until after the 2020 election when it thought Donald Trump was ...
US. They provide convincing evidence to support their conclusion that using the whole genome, rather than previous use of two surface proteins, enhances our understanding of strain-specific vaccine ...
Pharmaceutical Technology on MSN2d
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSKAbrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
A research team from the University of Minnesota Medical School has identified a strong predictor of ischemic stroke and dementia, a discovery that could lead to improved patient outcomes. The ...
Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...
Moderna stock dips 10% amid FDA resignation, signaling regulatory risks. Strong cash reserves can't offset competitive and ...
Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...
Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 10.67%, which has investors questioning if this is right time ...
The Western Journal on MSN5d
Bombshell: Prosecutors Question Timing of Pfizer Announcement Released Just After 2020 ElectionJust two days after Democrat Joe Biden was declared the winner of the 2020 presidential election, drugmaker Pfizer announced ...
Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot's success in 2020 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback